EGFR and non-small cell lung carcinoma: To determine the therapeutic relevance of these in vitro findings in vivo, we tested the efficacy of systemic administration of gefitinib and WZB-117 alone or in combination against subcutaneous xenografts of EGFR-wt NSCLC cells.